Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
Jesús García‐Foncillas(Hospital Universitario Fundación Jiménez Díaz), Sebastian Stintzing(Humboldt-Universität zu Berlin), Zev A. Wainberg(University of California, Los Angeles), Yu Sunakawa(St. Marianna University School of Medicine), Pauline Witzler(Merck (Germany)), Dan Aderka(Sheba Medical Center), Philippe Ronga(Merck (Germany))
Cited by 199
Related Papers
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS </i>Wild-Type Metastatic Colorectal Cancer
|JAMA Oncology|2016|722
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|614
The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials
|European Journal of Cancer|2016|533